Overview

Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy

Status:
No longer available

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

The objective of the trial is to provide regorafenib to subjects diagnosed with metastatic and / or unresectable GIST who have progressed after standard therapy. Selected additional safety information on regorafenib will be collected and progression-free survival (PFS) will be estimated.

Details

Lead Sponsor:

Bayer